# OnCo record nct06486441 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06486441/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06486441", "NCT06486441" ;
  schema:name "Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Im"@en ;
  schema:alternateName "ASCENT-GYN-01"@en ;
  schema:description "A phase 3 trial of Sacituzumab govitecan, Doxorubicin, Paclitaxel / nab-paclitaxel in endometrial cancer, run by Gilead Sciences, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06486441/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06486441> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2024-08-28" ;
  onco:cancers <https://onco.cc/cancers/endometrial/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/sacituzumab-govitecan/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/paclitaxel/> ;
  onco:companies <https://onco.cc/companies/gilead/> .